Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.

Szczegóły
Abstrakt

Tytuł:: Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Autorzy:: Jeon S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
Ko M; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
Lee J; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
Choi I; Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea.
Byun SY; Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
Park S; Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
Shum D; Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
Kim S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea .
Źródło:: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Jun 23; Vol. 64 (7). Date of Electronic Publication: 2020 Jun 23 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Washington, American Society for Microbiology
MeSH Terms:: Drug Repositioning*
Betacoronavirus/*drug effects
Coronavirus Infections/*drug therapy
Niclosamide/*pharmacology
Pneumonia, Viral/*drug therapy
Pregnenediones/*pharmacology
Animals ; Anti-Inflammatory Agents/pharmacology ; Antiviral Agents/pharmacology ; COVID-19 ; Cell Line ; Chlorocebus aethiops ; Drug Evaluation, Preclinical/methods ; Humans ; Pandemics ; SARS-CoV-2 ; Vero Cells
References:: ACS Infect Dis. 2020 May 8;6(5):909-915. (PMID: 32125140)
N Engl J Med. 2020 Mar 26;382(13):1199-1207. (PMID: 31995857)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
J Virol. 2020 Dec 9;95(1):. (PMID: 33055254)
Nature. 2020 Feb;578(7795):347-348. (PMID: 32071447)
Clin Pharmacol Ther. 1976 Jun;19(6):802-6. (PMID: 1269218)
J Infect Chemother. 2020 Jun;26(6):625-632. (PMID: 32362440)
Nat Commun. 2019 Dec 18;10(1):5770. (PMID: 31852899)
Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. (PMID: 15215127)
J Asthma Allergy. 2009 Feb 25;2:25-32. (PMID: 21437141)
Comput Struct Biotechnol J. 2020 Mar 30;18:784-790. (PMID: 32280433)
Nat Rev Drug Discov. 2004 Aug;3(8):673-83. (PMID: 15286734)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Contributed Indexing:: Keywords: COVID-19; FDA-approved drug; SARS-CoV-2
Substance Nomenclature:: 0 (Anti-Inflammatory Agents)
0 (Antiviral Agents)
0 (Pregnenediones)
8KK8CQ2K8G (Niclosamide)
S59502J185 (ciclesonide)
Entry Date(s):: Date Created: 20200506 Date Completed: 20200706 Latest Revision: 20240329
Update Code:: 20240329
PubMed Central ID:: PMC7318052
DOI:: 10.1128/AAC.00819-20
PMID:: 32366720
: Czasopismo naukowe

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC 50 s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.
(Copyright © 2020 American Society for Microbiology.)

Informacja